Rickels K
Am J Psychother. 1982 Jul;36(3):358-70. doi: 10.1176/appi.psychotherapy.1982.36.3.358.
The efficacy of the benzodiazepines in the symptomatic treatment of nonpsychotic anxiety has been well established. Eight benzodiazepines are presently available in the U.S. as anxiolytics. Research conducted over many years has shown that such nonpsychotic anxious patients respond best to anxiolytics if they suffer from high levels of emotional and somatic symptoms of anxiety and from low levels of depression and interpersonal problems. Despite the widespread use of benzodiazepines, it has been difficult to demonstrate tolerance or physical dependence to these drugs when used in therapeutic doses. In addition, data clearly indicate a pattern of conservative benzodiazepine use and possible an under- rather than overuse. Thus, the argument is made that cost-benefit ratios should be considered when discussing the use of benzodiazepines for the treatment of anxiety.
苯二氮䓬类药物在非精神病性焦虑的对症治疗中的疗效已得到充分证实。目前在美国有八种苯二氮䓬类药物作为抗焦虑药可供使用。多年来的研究表明,此类非精神病性焦虑患者若同时存在高水平的焦虑情绪和躯体症状,以及低水平的抑郁和人际问题,对抗焦虑药的反应最佳。尽管苯二氮䓬类药物被广泛使用,但在治疗剂量下使用这些药物时,很难证明会产生耐受性或身体依赖性。此外,数据清楚地表明存在苯二氮䓬类药物保守使用的模式,而且可能是使用不足而非过度使用。因此,有人认为在讨论使用苯二氮䓬类药物治疗焦虑时应考虑成本效益比。